Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
central nervous system
Biotech
MapLight illuminates $262M IPO plans to fund Cobenfy competitor
MapLight is hoping to raise up to $262 million from its IPO, with the proceeds earmarked for its challenger to Bristol Myers Squibb’s schizophrenia med Cobenfy.
James Waldron
Oct 7, 2025 6:30am
Julius attaches roots to Peachtree in CRO merger
May 14, 2025 2:52pm
Lilly saves gene therapy biotech with $18M upfront deal
Apr 3, 2025 6:00pm
Study reveals expanding gene that causes Huntington's disease
Jan 17, 2025 5:00pm
Sanofi inks $400M biobucks deal for Alloy's antisense platform
Jan 8, 2025 5:08am
AbbVie exercises $40M option for Capsida-partnered gene therapy
Jan 7, 2025 10:45am
